Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term pancreatic-cancer. Found 11 abstracts

Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas(dagger). Annals of Oncology. 2013 Jan;24(1):257-63.   PMCID: not NIH funded
Cukierman E, Bassi DE. The mesenchymal tumor microenvironment A drug-resistant niche. Cell Adhesion & Migration. 2012 May;6(3):285-96.   PMCID: PMC3427243
Kozloff MF, Martin LP, Krzakowski M, Samuel TA, Rado TA, Arriola E, Carpeno JD, Herbst RS, Tarazi J, Kim S, Rosbrook B, Tortorici M, Olszanski AJ, Cohen RB. Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. British Journal of Cancer. 2012 Oct;107(8):1277-85.   PMCID: PMC3494447
Gumbs AA, Rivera AM, Milone L, Hoffman JP. Laparoscopic Pancreatoduodenectomy: A Review of 285 Published Cases. Annals of Surgical Oncology. 2011 May;18(5):1335-41.   PMCID: not NIH funded
Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D. Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers. Clinical Cancer Research. 2010 Dec;16(24):6132-8.   PMCID: PMC3057907
Yang G, Chang B, Yang F, Guo XQ, Cai KQ, Xiao X, Wang HM, Sen S, Hung MC, Mills GB, Chang S, Multani AS, Mercado-Uribe I, Liu JS. Aurora Kinase A Promotes Ovarian Tumorigenesis through Dysregulation of the Cell Cycle and Suppression of BRCA2. Clinical Cancer Research. 2010 Jun;16(12):3171-81.   PMCID: PMC2930838
Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, Roberts DJ, Seiden MV, Scadden DT, Rueda BR, Foster R. CD133 Expression Defines a Tumor Initiating Cell Population in Primary Human Ovarian Cancer. Stem Cells. 2009 Dec;27(12):2875-83.   PMCID: not NIH funded
Slingluff CL, Petroni GR, Olson WC, Smolkin ME, Ross MI, Haas NB, Grosh WW, Boisvert ME, Kirkwood JM, Chianese-Bullock KA. Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8(+) and CD4(+) T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial. Clinical Cancer Research. 2009 Nov;15(22):7036-44.   PMCID: PMC 2778314
Arciero CA, Joseph N, Watson JC, Hoffman JP. Partial stomach-partitioning gastrojejunostomy for malignant duodenal obstruction. AMERICAN JOURNAL OF SURGERY. 2006 Mar;191(3):428-32.
Beacham DA, Cukierman E. Stromagenesis: The changing face of fibroblastic microenvironments during tumor progression. Seminars in Cancer Biology. 2005 Oct;15(5):329-41.
Montgomery RC, Ridge JA. Radiologic staging of gastrointestinal cancer. Seminars in Surgical Oncology. 1998 Oct;15(3):143-50.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term pancreatic-cancer

pancreatic-cancer breast-cancer metastatic colorectal-cancer 1st-line therapy adenocarcinoma carcinoma paclitaxel pre-operative care neoplasm staging small interfering rna stomach neoplasms tumor progression stromagenesis-extracellular matrix-microenvironment-3D culture systems-stromal mechanosensors positive reactions tyrosine kinase inhibitor endothelial cisplatin phase-ii trial liver neoplasms pathology metastatic melanoma portography false trial survival rate inhibitor acute lymphoblastic-leukemia dynamic ct endoscopic ultrasonography lymph-nodes ductal gastroenterostomy catalytic subunit a kinase myeloid suppressor-cells incidence cell lung-cancer soft-tissue sarcomas infusion sensitivity and specificity neoplasm recurrence lymphatic focal hepatic masses X-ray computed tomography in-vivo cells growth-factor laparoscopy colonic neoplasms multiple-myeloma cells nodes duodenopancreatectomy surgical palliation prostate-cancer growth minimal residual disease tumor-stromal interactions tumor microenvironment-stromal-induced drug resistance-extracellular matrix-tumor-associated or carcinoma-associated fibroblasts-matrix-induced drug resistance-mesenchymal stroma gemcitabine gene-expression antrectomy endosonography malignant obstruction complications surface epithelial-cells prospective identification false negative reactions local raf kinase magnetic resonance imaging growth neoplasm metastasis esophageal neoplasms bevacizumab angiosarcoma-hemangioendotheliomas-soft tissue sarcoma endoscopy adhesion-mediated drug adenocarcinomas chromosomal Human CD133-Ovarian cancer-Cancer stem cells-Tumor-initiating cells arterial portography bile-duct marker contribute peptide vaccine computed-tomography hepatocellular- multicenter differential diagnosis immunotoxin randomized-trial antitumor immunity barium sulfate focal adhesion kinase diagnostic errors bevacizumab clinical competence resection bone-marrow microenvironment 3-dimensional extracellular-matrix peritoneal mesothelioma clinical-outcomes ultrasonography prophylactic gastrojejunostomy pylorus-preserving pancreaticoduodenectomy c-myc ss1p gastric outlet obstruction reconstruction pancreatic neoplasms positive cells experience diagnosis ovarian-cancer rectal neoplasms stem-cells Surgery contrast media recombinant angiography gastric-cancer gastrointestinal neoplasms breast-cancer cells chemotherapy axitinib-pharmacokinetics-solid tumours-non-small cell lung cancer poor-prognosis metastasis reactive stromal fibroblasts endothelial growth-factor colorectal-carcinoma lymph plus bevacizumab surgery activation protein tgf-beta collagen-matrix radiography gm-csf dendritic instability stomach-partitioning gastrojejunostomy predictive value of tests mitotic checkpoint unresectable periampullary cancer hmg-coa reductase palliation endothelial-cells
Last updated on Tuesday, August 04, 2020